Baird Medical Investment Holdings Ltd Ordinary Share
BDMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BDMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BDMD
Baird Medical Investment Holdings Ltd is a China-based medical device company focused on developing and commercializing microwave ablation systems for thyroid treatment, with an active R&D pipeline in AI-integrated robotic systems.
Key risk: Liquidity risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Baird Medical Investment Holdings Ltd is a China-based medical device company focused on developing and commercializing microwave ablation systems for thyroid treatment, with an active R&D pipeline in AI-integrated robotic systems.
- Revenue declined from $37.0M in 2024 to $22.5M in 2025, while net income swung to a loss of $27.3M in 2025 [sec · filed 2026-04-24].
- Cash and equivalents were $0.6M as of December 31, 2025, with a working capital balance of $22.6M [sec · filed 2026-04-24].
- The company's core product is a thyroid microwave ablation system, and it is developing AI-integrated robotic systems for thyroid treatment [sec · filed 2026-04-24].
- Gross profit margin improved from 86.6% in 2023 to 88.2% in 2024, but fell to 83.8% in 2025 [sec · filed 2026-04-24].
- The controlling shareholder and CEO have expressed intention to provide financial support for at least 12 months from the date of the 2025 financial statements [sec · filed 2026-04-24].
What works
- The company has a proven commercialized product (thyroid microwave ablation system) and a high gross profit margin (88.2% in 2024) [sec · filed 2026-04-24].
- It is pursuing a differentiated full-stack strategy combining hardware, software, and AI, targeting a specialized global market [sec · filed 2026-04-24].
- The controlling shareholder and CEO have committed to providing financial support to ensure continued operations for at least 12 months [sec · filed 2026-04-24].
What to weigh
- Revenue dropped sharply from $37.0M in 2024 to $22.5M in 2025, and the company reported a net loss of $27.3M in 2025 [sec · filed 2026-04-24].
- Cash and equivalents were only $0.6M as of December 31, 2025, indicating tight liquidity [sec · filed 2026-04-24].
- Pipeline products (Class III medical devices) face uncertain regulatory timelines and testing schedules controlled by third parties [sec · filed 2026-04-24].
- The company incurred an administrative penalty in November 2024, contributing to higher other expenses [sec · filed 2026-04-24].
From the filings
Quoted directly from source documents.
Core technology and mission
“Our core strengths lie in our successful development and commercialization of the thyroid microwave ablation system, as well as our active R&D pipeline featuring AI-integrated robotic systems.”
SEC filings · April 24, 2026
Financial support commitment from controlling shareholder
“Betters Medical Investment Holdings Limited, the controlling shareholder of the Company, together with Haimei Wu, the Chairwoman of the Board of Directors and Chief Executive Officer of the Company, confirmed that their current intention was to provide adequate financial support to us as is necessary to ensure our continuing operation for a period of at least 12 months”
SEC filings · April 24, 2026
Risks & what to watch (4)›
Key risks
- Liquidity risk — Cash of only $0.6M as of Dec 31, 2025, with reliance on shareholder support and potential dilutive financing [sec · filed 2026-04-24].
- Regulatory approval delays — Pipeline Class III devices depend on third-party testing schedules beyond company control [sec · filed 2026-04-24].
- Revenue volatility — Revenue fell from $37.0M in 2024 to $22.5M in 2025, with net loss of $27.3M [sec · filed 2026-04-24].
- Litigation and penalties — Administrative penalty in Nov 2024 increased other expenses; litigation could disrupt operations [sec · filed 2026-04-24].
What to watch
- Ability to stabilize or grow revenue after the sharp decline in 2025 [sec · filed 2026-04-24].
- Progress of pipeline products through NMPA registration testing and clinical trials [sec · filed 2026-04-24].
- Cash runway and any additional debt or equity financing activities [sec · filed 2026-04-24].
- Execution of the AI-integrated robotic system development and commercialization [sec · filed 2026-04-24].
Sources: SEC filings · Generated August 10, 2026 · How we verify sources →
Run Baird Medical Investment Holdings Ltd Ordinary Share through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Baird Medical Investment Holdings Ltd Ordinary Share facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
37.7 months
D/E 1.23 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$740K
| Holder | Shares | Value |
|---|---|---|
| highbridge capital management llc | 125,000 | $230K |
| jpmorgan chase & co | 125,000 | $230K |
| two sigma investments, lp | 46,587 | $91K |
| jane street group, llc | 39,416 | $77K |
| geode capital management, llc | 25,442 | $50K |
| morgan stanley | 20,000 | $39K |
| national bank of canada /fi/ | 11,700 | $22K |
| wolverine asset management llc | 205 | $402 |
Short Interest
as of May 20, 2026- % of float
- 2.9%
- Days to cover
- 0.8
- Shares short
- 218,817
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BDMD short interestFrequently asked questions
What is the AI investment thesis for Baird Medical Investment Holdings Ltd Ordinary Share?
Baird Medical Investment Holdings Ltd is a China-based medical device company focused on developing and commercializing microwave ablation systems for thyroid treatment, with an active R&D pipeline in AI-integrated robotic systems.
Who is the CEO of Baird Medical Investment Holdings Ltd Ordinary Share?
Ms. Haimei Wu is the chief executive officer of Baird Medical Investment Holdings Ltd Ordinary Share (BDMD).
Where is Baird Medical Investment Holdings Ltd Ordinary Share headquartered?
Baird Medical Investment Holdings Ltd Ordinary Share (BDMD) is headquartered in Guangzhou, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.